|
|
Article: NewCo News: Novartis Deal Brings Synosia Its Sixth CNS Compound.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
While most biotechs hope to one day license their products to a big pharma partner, Synosia Therapeutics is doing just the opposite.
Earlier this year, the San Francisco-based company licensed five drug candidates from F. Hoffmann-La Roche Ltd., and on Monday it announced a license for a sixth and an option for a seventh from Novartis AG.
The ability to obtain access to "clinically-enabled compounds sitting on the shelf at big pharma" is part of what makes Synosia unique, said President and CEO Ian Massey.
In fact, the company was founded to take advantage of the "significant discovery investment" made by big pharma in the ...